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ABSTRACT
Introduction: Previous studies have found
higher rates of adherence in patients with type
2 diabetes mellitus (T2DM) using insulin pens
compared to vial and syringe administration;
however, little evidence is available to support
this observation in elderly patients.
Methods: This was a retrospective claims
database analysis of a predominantly elderly
Medicare Advantage with Prescription Drug
(MAPD) insurance population consisting of
3172 insulin-naı¨ve patients with T2DM who
initiated basal insulin using pre-filled pens or
vial and syringe (‘vial’). The index date was
defined by the first pharmacy claim for basal
insulin. Adherence, measured as proportion of
days covered (PDC) and medication possession
ratio (MPR), and persistence were evaluated in a
12-month follow-up period using an adjusted
days’ supply. Multivariate regression analyses
and a Cox proportional hazards model were
used to identify characteristics associated with
adherence and non-persistence, respectively,
and compare findings between the pen and
vial groups.
Results: The pen cohort was slightly younger
than the vial cohort (69.4 vs. 70.1 years,
respectively; P = 0.0338). Similar proportions
of male patients (53.3% vs. 56.8%; P = 0.0529)
occurred in both cohorts, and lower
Deyo–Charlson Comorbidity Index (4.4 vs.
5.0; P\0.0001) was found for the pen cohort.
Adjusted mean PDC was significantly higher in
the pen cohort than the vial cohort (0.67 vs.
0.50; P\0.001), as was mean MPR (0.75 vs.
0.57; P\0.0001). Adjusted odds for adherence
(PDC C 80%) showed a positive association with
use of an insulin pen (odds ratio = 2.19, 95% CI:
1.86–2.59). The adjusted risk of non-persistence
(discontinuation) was significantly lower (58%)
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in the pen cohort relative to the vial cohort
(hazard ratio = 0.42, 95% CI: 0.38–0.45). Key
limitations include assumptions related to
accuracy and comprehensiveness of claims
data, and specifically days’ supply data used to
measure insulin adherence.
Conclusion: These findings suggest that pen
devices improved insulin therapy adherence in
a primarily elderly MAPD population with
T2DM.
Funding: Novo Nordisk Pharmaceuticals, Inc.
Keywords: Adherence; Basal insulin; Elderly;
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INTRODUCTION
The incidence of complications in patients with
type 2 diabetes mellitus (T2DM) can be reduced
by appropriate glycemic control, and there is
general consensus that insulin therapy should
be started in patients who fail to achieve
glycemic control targets with one or more
non-insulin antidiabetic agents [1–3]. Lower
comorbidity prevalence and severity have been
reported for patients with early adoption and
high adherence to insulin therapy [4]. However,
patients and providers often delay insulin
initiation due to well-described barriers, such
as fear of needles or the inconvenience of
injections compared to oral therapies [5].
Insulin therapy is also associated with
potentially serious hypoglycemic consequences
if not managed properly. Pre-filled, disposable
insulin pens, which have been available since
the 1980s, offer an administration option that
may be considered preferable by some patients.
Previous reports have shown improved
adherence and persistence primarily in
commercially insured patients using insulin
pen devices compared to those using
traditional vial and syringe administration
[6–8].
In elderly or debilitated patients, in
particular, pre-filled insulin pens may offer
advantages such as improved dose accuracy
and consistency, greater convenience, greater
ease of physical manipulation, and use needles
that incur less pain upon injection [9].
However, pen devices are typically more
costly, may take longer to administer, and are
not available for all insulins [9]. Ultimately, the
consistency with which patients use an
administration device will affect the clinical
results achieved. Prior studies evaluating
adherence and persistence with insulin pens
versus vials have typically evaluated single
insulin products and have been based on
general diabetes populations, not specifically
the elderly [6, 7, 10–12]. One exception is a
recent study by Miao et al. [13] that reported
improved persistence and adherence to insulin
administration in elderly Medicare patients
with T2DM who initiated or switched to
disposable pens compared with vial and
syringe. Even less is known about the drivers
of adherence to insulin therapy in elderly
patients with T2DM who are likely to have
higher mortality and complications compared
with younger patients with T2DM and age
group peers without T2DM [14–16].
The objective of this study was to evaluate
patient characteristics associated with
adherence and persistence to insulin therapy
in a Medicare Advantage with Prescription Drug
(MAPD) insurance population comprised
primarily of elderly health plan members who
were insulin-naı¨ve and who started a basal
insulin regimen using disposable pen or vial
and syringe.
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METHODS
Data Source
This was a retrospective analysis using medical
and pharmacy claims, laboratory results, and
patient characteristics obtained from a large US
national health plan (Humana, Inc.). The study
was limited to claims of Humana members
enrolled in an MAPD plan. The research
protocol was reviewed and approved prior to
study initiation by an independent Institutional
Review Board and was granted a waiver of
Health Insurance Portability and
Accountability Act authorization and a waiver
of informed consent.
Subject Selection
The criteria for patient selection included: age
between 18 and 89 years; evidence of basal
insulin use [insulin detemir, insulin glargine,
or insulin isophane (NPH)]; and a diagnosis of
T2DM at any time during the identification
period (July 1, 2010 through September 30,
2011). T2DM was defined by any of the
following criteria: (1) two or more prescription
fills for oral antidiabetic medications (OADs) or
a glucagon-like peptide-1 agonist; (2) one or
more medical claims with a primary diagnosis
of T2DM [International Classification of
Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) code 250.x0 or 250.x2]; or (3) two
or more medical claims with a secondary
diagnosis of T2DM on different dates. The
index date for each patient was defined as the
first pharmacy claim for basal insulin during the
identification period. All patients were required
to have at least 12 months of continuous
enrollment for the 12 months before and after
the index date. The attrition diagram (Fig. 1)
outlines additional inclusion and exclusion
criteria.
Baseline Characteristics
Baseline demographic characteristics examined
included age, sex, geographic region (Northeast,
Southeast, Midwest, and West), population
density (urban, suburban, and rural), race/
ethnicity (White, Black, Hispanic, and other),
and plan characteristics [low income subsidy
(LIS) status and dual eligibility for Medicare and
Medicaid]. Population density was assigned by
matching patient zip codes to Rural–Urban
Commuting Area (RUCA) codes [17] and
applying the Washington State Department of
Health’s RUCA consolidation system [18].
Clinical characteristics measured during the
baseline period included the Deyo–Charlson
Comorbidity Index (Deyo-CCI) [19]. The CCI
is a disease-based indicator derived from data
from medical records, which was designed to
assess the risk of 1-year mortality among
inpatients on a medical service. The Deyo-CCI
is an adaptation of the CCI, which adjusts the
index to administrative claims research via
mapping to ICD-9-CM diagnoses and
procedure codes. Clinical characteristics were
also measured using an adapted diabetes
complications severity index (DCSI), which
quantifies the severity of a wide range of
diabetes complications. The adapted version
has been proven to be accurate using claims
data in the absence of laboratory data [20, 21].
Further characteristics examined included use
of non-insulin injectable products during the
pre-index period, oral antidiabetic use during
the pre-index period, prescribing physician
specialty, pre-index count of glycated
hemoglobin (HbA1c) tests performed, number
of physician office visits, and number of
prescription claims.
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Fig. 1 Attrition diagram. T2DM type 2 diabetes mellitus
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Outcome Measures
Outcomes of interest included adherence,
persistence, and time-to-discontinuation. Due
to the customization of insulin dosing,
differences in package sizes (commonly 1000
units for insulin vials and 1500 units in a
package of insulin pens), expiration dates,
patient usage, and inaccuracies in the days’
supply entered at pharmacies, it can be
problematic to use the days’ supply field
directly from pharmacy claims when
calculating adherence and persistence to
insulin. Despite these differences, insulin
prescriptions are most often dispensed as a
30 days’ supply. This presents a challenge
when making comparisons of adherence and
persistence between basal insulin supplied as
insulin-filled pen devices and that supplied in
vials. To address these issues, a days’ supply
adjustment factor was calculated for each basal
insulin-delivery device combination (6 in total)
in a manner similar to that described by
Buysman et al. [6]. A unique adjustment factor
was established for each insulin-delivery device
combination because each insulin may be
packed in quantities different from the others,
have a different shelf-life, and/or be dosed
differently by providers. Specifically, the
following steps were followed to calculate the
adjusted days’ supply, as a measure of
adherence for all basal insulin pharmacy claims:
1. Patients from the study sample with C2
prescription claims for basal insulin were
identified. Patients in this sample were
required to be insulin-naı¨ve prior to the
index date and meet all other study criteria
described above in subject selection.
2. Days’ supply reported on each pharmacy
claim and the time between pharmacy
claims for basal insulin was determined for
these patients.
3. The adjustment factor was calculated as the
ratio of the median time between insulin
claims divided by the median pharmacy
reported days’ supply for each basal
insulin-delivery device combination.
4. An adjusted days’ supply was calculated for
the final study sample by multiplying the
actual days’ supply reported on each
pharmacy claim by the adjustment factor
for the appropriate basal insulin-delivery
device combination. The adjustment factors
were 1.80 and 1.30 for pen and vial,
respectively, for insulin glargine; 1.87 and
1.33, respectively, for insulin detemir; and
1.73 and 1.37, respectively, for insulin
isophane (NPH).
Adherence was measured using the proportion
of days covered (PDC), as well as the medication
possession ratio (MPR). The PDC is a newer and
more conservative measure of adherence than
the MPR [22, 23]. The PDC and MPR are similar
in that the days’ supply from pharmacy claims
is used to calculate adherence for both, but they
differ in their approach to determining how
days’ supply is used to calculate the numerator
used for the calculations. MPR is most
commonly calculated by summing the days’
supply from all claims for a study drug and then
dividing by the number of days from drug
initiation to the end of drug persistence.
Because all days’ supplies are included, even
when early refills occur or a patient switches
medications within the same class, the ratio of
days’ supply to days in the study period can
potentially be[1.0. When calculating PDC, the
numerator is the total number of covered days
during the study period, regardless of how
many prescription claims are available on any
single day. Each day in the study period is
independently evaluated for coverage by the
study drug, and the maximum PDC is therefore
1.0.
1210 Adv Ther (2015) 32:1206–1221
The covered days for each prescription began
on the fill date and lasted for the duration of the
adjusted days’ supply. Days spent in a hospital
setting were counted as days with medication
available. Days of insulin possession from a
previous fill that overlapped with a subsequent
fill were not double-counted, but they were
instead removed from the calculation of the
adherence measures. Furthermore, no
adjustment to the start date of a new
prescription was made in instances where
there were overlapping days for the same
medication. Adherence was reported as both a
continuous variable (0–100%) and a
dichotomous one with a threshold of C80%
PDC considered ‘adherent.’ Persistence was
measured as the number of days of continuous
basal insulin coverage (using adjusted days’
supply) prior to a gap in medication coverage.
Given the use of adjustment factors in the
calculation in the adjusted days’ supply, a
conservative gap threshold of one or more
days was employed to identify non-persistence
[6].
Examinations of adherence and persistence
to insulin that use the reported days’ supply
directly from pharmacy claims data without
adjusting for the weaknesses mentioned are of
limited value. Their weaknesses include varying
package sizes and dosing schedules, which are
frequently not accounted for in the reported
days’ supply. Pharmacy claims most frequently
report a 30 days’ supply even if the patient will
have insulin left after 30 days if taken at the
prescribed dose. For this reason, the present
study used adjustment factors to accommodate
for the difficulties in calculating adherence to
insulin using a claims database. A unique
adjustment factor was calculated for each of
the 6 basal insulin-delivery device
combinations included in this study, and all
adjustment factors were [1, thereby
lengthening the days’ supply for all of the
basal insulin pharmacy claims.
The change in the HbA1c value from the
pre-index period to the post-index period was
not a primary outcome measure, and therefore
not all patients in the study were required to
have both pre-index and post-index HbA1c
values. However, among patients with
laboratory values available in both time
periods, this measure was assessed as a
measure of glycemic control.
Statistical Analysis
Univariate descriptive statistics were used to
compare demographic (age, sex, race, etc.) and
clinical characteristics (Deyo-CCI, oral
antidiabetic use during the baseline period,
number of physician office visits, etc.) between
the two study cohorts. Differences in baseline
characteristics were assessed using ANOVA for
continuous variables (age and comorbidity
index score) and Chi-square tests for
categorical variables (sex and geographic
region). The difference in HbA1c from baseline
to follow-up was assessed using Student’s t test.
The study compared mean PDC (as a
measure of adherence) and mean persistence
(in days) between the two study cohorts (pen vs.
vial) using t tests. The proportion of each study
cohort above the adherence threshold of 80%
was compared using the Chi-square test. A
cutoff of 80% is frequently used as the
threshold when measuring adherence as a
dichotomous variable [6]. MPR values were
also calculated and compared between the two
cohorts in a similar fashion.
Multivariable regression analyses were
performed to identify characteristics associated
with increased adherence using linear
regression for continuous PDC and logistic
regression for dichotomous adherence with an
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80% PDC threshold. Persistence was analyzed
using a Cox proportional hazards model. All
reported demographic and clinical
characteristics, including whether the patient
was classified in the pen or vial cohort, were
added to the statistical models. All analyses of
data were conducted using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA). The a priori
alpha level for all inferential analyses was set at
0.05, with all statistical tests being two-tailed,
unless otherwise specified.
RESULTS
A sample of 3172 MAPD patients meeting all
study criteria was identified, including 1941 in
the pen cohort, and 1231 in the vial cohort. The
demographic and clinical characteristics of the
two cohorts are presented in Tables 1 and 2.
Mean age in the pen cohort was 69.4 years
compared with 70.1 years in the vial cohort
(P = 0.0338), and the percentage of males was
similar in the two groups (53.3% and 56.8%,
respectively; P = 0.0529). A significantly higher
proportion of the pen cohort patients resided in
the Midwest compared to the vial cohort
(29.4% vs. 18.2%; P\0.0001) while a lower
proportion resided in the South (59.3% vs.
71.3%; P\0.0001). A significantly higher
proportion of the pen cohort was made up of
patients classified as White (80.8% vs. 75.4%),
while a lower proportion was comprised of
patients classified as Black (14.3% vs. 18.3%)
and Hispanic (1.8% vs. 3.2%; P = 0.0009 for all).
Pen use was more prevalent in suburban areas
(25.6% vs. 21.4%) and less prevalent in urban
areas (63.7% vs. 67.0%; P = 0.0037 for all).
Equal proportions of the rural areas used both
delivery devices.
Both the Deyo-CCI and DSCI were
significantly lower in the pen cohort
compared with the vial cohort (Deyo-CCI: 4.4
vs. 5.0; P\0.0001; DCSI: 3.8 vs. 4.3; P\0.0001;
Table 2). A large majority of patients was
prescribed insulin by a primary care physician
(PCP; pen 76.4%, vial 78.1%). However, a
higher proportion of the pen cohort compared
with the vial cohort was prescribed index basal
insulin by an endocrinologist (7.3% vs. 3.7%;
P\0.0001), and a smaller proportion received
prescriptions from an emergency medicine
practitioner (0.5% vs. 1.5%; P = 0.003). Use of
oral antidiabetic agents during the baseline
period, number of HbA1c tests performed, and
the number of physician office visits during the
baseline period were significantly higher in the
pen cohort than in the vial cohort (P\0.0001
in all cases). All differences in baseline
characteristics between the cohorts were
accounted for in the multivariate models used
to compare adherence and persistence as
measured by the PDC.
Adherence
Results of the adherence analyses are presented
in Table 3. Unadjusted and adjusted PDC values
were significantly higher in the pen cohort than
in the vial cohort (unadjusted PDC, 71% vs.
53%; P\0.001; adjusted PDC, 67% vs. 50%;
P\0.001), as were the MPR values (0.75 vs.
0.57; P\0.0001). The proportion of patients
with a PDC C80% was significantly higher in
the pen versus the vial cohort (49.4% vs. 29.7%;
P\0.001), as was the proportion of patients
with an MPR C80% (57.9% vs. 35.4%;
P\0.0001).
On multivariate analysis, the adjusted odds
of being adherent (PDC C 80%) showed a
positive relationship between use of an insulin
pen and being adherent (odds ratio = 2.19,
95% CI: 1.86–2.59). No significant difference
in the odds of adherence was seen between
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patients prescribed their index prescription by
an endocrinologist relative to a PCP. Additional
relationships are described in Table 4.
Persistence
The unadjusted mean persistence was
significantly longer in the pen cohort than in
the vial cohort (181.0 days vs. 93.7 days;
P\0.0001), and the adjusted risk [hazard ratio
(HR)] of non-persistence (discontinuation) was
58% lower (HR = 0.415, 95% CI: 0.381–0.452;
Table 3) in the pen cohort relative to the vial
cohort. The pen cohort also had significantly
more basal insulin prescription fills prior to
discontinuation (mean number of claims: 2.93
vs. 2.13; P\0.0001; Table 3). As with
adherence, no significant difference was found
in the risk of non-persistence between those
prescribed their index basal insulin prescription
by an endocrinologist compared to a PCP.
The Cox proportional hazard model
examining the characteristics associated with
non-persistence revealed that, as with
adherence, no significant relationship was
found between the prescribing of basal insulin
Table 1 Baseline demographic characteristics
Characteristic Pen cohort (n 5 1941) Vial cohort (n5 1231) P value
Age, years, mean (SD) 69.4 (8.6) 70.1 (8.6) 0.0338
Male gender, n (%) 1034 (53.3) 699 (56.8) 0.0529
Geographic region, n (%) \0.0001
Northeast 37 (1.9) 18 (1.5)
Midwest 571 (29.4) 224 (18.2)
South 1151 (59.3) 878 (71.3)
West 182 (9.4) 111 (9.0)
Population density, n (%) 0.0037
Urban 1236 (63.7) 825 (67.0)
Suburban 497 (25.6) 264 (21.4)
Rural 200 (10.3) 127 (10.3)
Race/ethnicity, n (%) 0.0009
White 1568 (80.8) 928 (75.4)
Black 277 (14.3) 225 (18.3)
Hispanic 35 (1.8) 39 (3.2)
Other 61 (3.1) 39 (3.2)
LIS status only, n (%) 153 (7.9) 95 (7.7) 0.8659
Dual eligibility onlya, n (%) 9 (0.5) 6 (0.5) 0.9244
LIS status and dual eligibilitya, n (%) 128 (6.6) 107 (8.7) 0.0279
LIS low income subsidy, SD standard deviation
a Dual eligibility for Medicare and Medicaid
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by an endocrinologist as compared with a PCP.
However, all other prescriber types had a
statistically significantly higher HR relative to
PCP prescribers, indicating higher risk of
non-persistence on basal insulin (data not
shown).
Change in HbA1c Values
A subgroup of 817 patients in the pen cohort
and 558 patients in the vial cohort had HbA1c
laboratory values available during both the
baseline and follow-up periods. The difference
in HbA1c from baseline to follow-up was found
to be significantly greater for the pen cohort
than for the vial cohort (-0.80% vs. -0.60%;
P = 0.0473).
DISCUSSION
This study in a mostly elderly T2DM population
enrolled in an MAPD plan and newly started on
basal insulin therapy found significant
differences in a variety of characteristics
between patients using pens and those using
vials and syringes. Patients using pens tended to
be have fewer comorbidities, and the ethnic and
geographic distributions differed between the
Table 2 Baseline clinical characteristics
Characteristic Pen cohort (n5 1941) Vial cohort (n5 1231) P value
Deyo-CCI, mean (SD) 4.4 (2.8) 5.0 (3.0) \0.0001
DCSI Score, mean (SD) 3.8 (2.5) 4.3 (2.6) \0.0001
Non-insulin injectable usea, n (%) 226 (11.6) 119 (9.7) 0.0814
Oral antidiabetic usea, n (%) 1806 (93.0) 1034 (84.0) \0.0001
Count of HbA1c tests performeda, mean (SD) 3.7 (2.3) 3.3 (2.7) \0.0001
Number of physician ofﬁce visitsa, mean (SD) 35.7 (29.0) 33.4 (31.3) 0.0001
Number of prescription claimsa, mean (SD) 168.4 (95.9) 174.2 (104.9) 0.3491
Prescribing physician specialty, n (%)
Primary care 1482 (76.4) 962 (78.1) 0.2413
Endocrinologist 142 (7.3) 46 (3.7) \0.0001
Emergency medicine 10 (0.5) 19 (1.5) 0.003
Other 254 (13.1) 170 (13.8) 0.5593
Unknown 53 (2.7) 34 (2.8) 0.9579
Index insulin, n (%)
Insulin glargine 1398 (72.0) 891 (72.4) 0.8277
Insulin detemir 528 (27.2) 163 (13.2) \0.0001
Insulin isophane (NPH) 15 (0.8) 177 (14.4) \0.0001
DCSI Diabetes Complication Severity Index, Deyo-CCI Deyo–Charlson Comorbidity Index, HbA1c glycated hemoglobin,
SD standard deviation
a During the pre-index period
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two groups. However, when adjusting for the
differences between the two groups, it was clear
that those using pens to deliver basal insulin
had a significantly higher rate of adherence and
persistence than those administering basal
insulin via vial and syringe. This analysis is
unique in that it used the PDC, as well as the
MPR, to evaluate adherence to basal insulin.
Furthermore, the study population differed
from those in previous studies, being an
MAPD population consisting primarily of
elderly health plan members (aged 65 years
and older). Thus, this study provides a
different perspective on insulin use among this
demographic, one of the fastest growing
segments of US society in general and one that
has a high burden of diabetes disease.
In this analysis, the adjusted overall odds
ratio favoring adherence was higher for patients
using pens than vials. The adjusted mean rates
of adherence (0.71 and 0.53 for the pen and vial
cohorts, respectively) are on the high end of the
ranges reported in previous studies (0.53–0.69
for the pen cohort and 0.38–0.62 for the vial
cohort) [6, 8, 24] despite the use of the PDC
calculation, which allows for a more
conservative approach to evaluating
medication adherence to insulin use [6, 8, 11].
This difference may be due to the use of the
days’ supply adjustment factor, which was[1
for all six of the basal insulin-delivery device
combinations and, therefore, increased the
days’ supply of all of the pharmacy claims
used in the study. These adjustments reflect
the fact that most basal insulin prescriptions
last longer than the 30 days’ supply that is
typically reported in pharmacy claims. The
adjusted days’ supply used in this study may
more accurately represent the true number of
days with insulin supply available to the
Table 3 Adherence and persistence measures
Measure Pen cohort Vial cohort P value
Number of prescription claims prior to discontinuation, mean (SD) 2.93 (2.9) 2.13 (2.5) \0.0001
Adherence
Mean adherence (MPR) 0.75 (±0.3) 0.57 (±0.3) \0.0001
Mean adherence (PDC)
Unadjusted mean (95% CI) 0.71 (0.70, 0.73) 0.53 (0.52, 0.55) \0.0001
Adjusted mean (95% CI) 0.67 (0.61, 0.72) 0.50 (0.45, 0.56) \0.0001
Proportion adherent (MPR C80%), n (%) 1123 (57.9) 436 (35.4) \0.0001
Proportion adherent (PDC C80%), n (%) 959 (49.4) 366 (29.7) \0.0001
Adjusted odds of adherence (PDC C80%) (95% CI) 2.19 (1.86, 2.59) Reference \0.0001
Persistence
Unadjusted mean persistence, days (SD) 181.0 (128.1) 93.7 (89.8) \0.0001
Adjusted hazard ratio (95% CI) 0.415 (0.381, 0.452) Reference \0.0001
Mean basal insulin ﬁlls prior to discontinuation 2.93 2.13 \0.0001
All reported demographic and clinical characteristics were included in the adjusted models
CI conﬁdence interval, MPR medication possession ratio, PDC proportion of days covered, SD standard deviation
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Table 4 Logistic regression of adherence (PDC C 80%)
Parameter Odds ratio 95% CI P value
Lower Upper
Cohort (pen = 1, vial = 0) 2.19 1.86 2.59 \0.0001
Age 1.00 0.99 1.01 0.638
Deyo-CCI score 0.95 0.91 0.98 0.004
DCSI score 0.98 0.94 1.02 0.412
Number of prescription claimsa 1.00 1.00 1.00 \0.0001
Male sex 1.04 0.89 1.21 0.635
Count of HbA1c tests performeda 1.04 1.01 1.08 0.017
Index basal insulin product
Insulin detemir 0.98 0.82 1.18 0.867
Insulin isophane (NPH) 1.26 0.90 1.75 0.173
Insulin glargine Ref.
LIS status and dual eligibility 1.19 0.89 1.58 0.244
Non-insulin injectable usea 1.02 0.80 1.30 0.876
Count of physician ofﬁce visitsa 1.00 0.99 1.00 0.009
Oral antidiabetic usea 1.21 0.93 1.57 0.162
Index prescriber type
Endocrinologist 0.96 0.71 1.32 0.819
ER physician 0.40 0.16 1.02 0.055
Other 0.72 0.58 0.90 0.004
Unknown 0.70 0.44 1.12 0.136
Primary care Ref.
Population density
Suburban 1.23 1.03 1.47 0.020
Rural 1.33 1.04 1.70 0.025
Unknown 0.78 0.31 1.98 0.603
Urban Ref.
Geographic region
Northeast 1.52 0.87 2.66 0.144
Midwest 1.47 1.23 1.76 \0.0001
West 1.56 1.20 2.02 0.001
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patients, thus providing a more accurate
calculation of adherence and persistence to
insulin therapy. The difference in adherence
may also be a result of the differences between
the populations that could not be accounted for
using the available data, and the use of PDC for
calculating adherence as opposed to the MPR
calculation used in previous investigations [6, 8,
11].
The regression analyses examining
characteristics associated with adherence and
persistence to basal insulin therapy showed
several similarities. First, mean adherence and
persistence were higher in the pen cohort,
which corroborates findings from previous
studies [6, 8, 11]. Second, patients’ geographic
region and population density were observed to
affect adherence and persistence. Residence
outside of the Southern US showed positive
associations with both adherence and
persistence. The reasons for these associations
are not immediately evident, but are
undoubtedly multifactorial.
Among the subset of patients for whom pre-
and post-index HbA1c data were available,
larger decreases in HbA1c, indicating better
glycemic control, were observed in the pen
cohort compared with the vial cohort. While
not a primary outcome of this study, this
subgroup analysis showed a trend between
higher adherence and larger decreases in
HbA1c values. Long-term investigations of the
effect of glycemic control on outcomes have
demonstrated that improvements in glycemic
control are associated with decreases in both
microvascular and neuropathic complications
of diabetes [25–27] and have shown trends
suggesting lower overall cardiovascular risks
[28].
Interestingly, the baseline characteristics of
the two cohorts highlighted that pen use was
more prevalent in suburban areas and less
prevalent in urban areas. Patients in urban
areas were more likely to use vials over pen
devices. Furthermore, a higher proportion of
the pen cohort resided in the Midwest, while a
higher proportion of the vial cohort resided in
the South. This suggests that there may be
regional differences in providers’ prescribing
patterns. Additional examination of this trend
is needed to understand the implications of
these observations.
There have been several previous studies
comparing rates of adherence [6–8, 11, 24, 29]
and persistence [6, 8, 12] among patients using
insulin pens versus vials using administrative
claims databases. The results of the current
study support the findings from previous
studies that showed higher rates of adherence
with insulin pens than with vials and syringes.
For example, Buysman et al. [6] compared
adherence and persistence between patients
Table 4 continued
Parameter Odds ratio 95% CI P value
Lower Upper
South Ref.
Dependent variable for logistic regression model = adherent. Odds ratios[1.0 indicate higher odds of being adherent
CCI Charlson Comorbidity Index score, DCSI Diabetes Complication Severity Index score, ER emergency room, LIS low
income subsidy, PDC proportion of days covered, ref. reference
a During the pre-index period
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initiating basal insulin therapy with either
insulin detemir in a pen or insulin isophane
(NPH) in a vial, and found that patients on the
insulin detemir pen had 39% higher odds of
adherence (MPR C80%) and a 38% lower hazard
of discontinuation. A similar investigation by
Davis et al. [12] showed that patients initiating
insulin glargine in a pen versus vial were
significantly less likely to discontinue therapy
or switch to another therapy. In several studies
that also reported costs, the improved
adherence and/or persistence was achieved
without increasing overall healthcare costs [7,
11–13, 24]. Miao et al. [13], in a study based on a
Medicare population, noted better persistence
and adherence with insulin therapy prescribed
as a pen compared with a vial, with no increase
in total health care costs.
Several studies have examined the impact of
adherence to oral antidiabetic therapies on
clinical and economic outcomes [20–37].
These other investigations have included
outcome measures such as glycemic control
(HbA1c laboratory values) [35, 36], health care
resource utilization [31, 32, 34, 37], and
healthcare costs [33, 37], all of which were
found to improve with higher rates of
adherence, and are in agreement with results
in the current study with insulin therapy.
The study cohorts were found to be
significantly different in several important
baseline demographic and clinical
characteristics, which partly could have been
due to the large numbers of patients in each
cohort. Multivariate analyses were used to
adjust for many of the characteristics known
to be associated with medication adherence and
persistence, such as age and level of
comorbidity. However, there may be
additional confounders that were not available
for inclusion.
While the PDC, which is a more conservative
measure of adherence, was chosen in the present
study, this method does have limitations. For
example, in calculating of PDC, it was not
possible to adjust the starting date for
overlapping prescription fills. Therefore, this
method does not account for patients who may
fill a prescription early but continue to use the
remaining supply from the earlier prescription
and may, therefore, underreport adherence.
There are other limitations inherent to
claims database research. First, claims data
are prone to coding errors, and they may not
reflect actual disease or therapies. While
pharmacy claims accurately represent all
prescriptions that are filled, they may not
give a true depiction of actual medication use.
It was assumed that patients were filling
insulin prescriptions as the drug was needed,
and they were not hoarding, wasting, or
discarding unused insulin. Furthermore,
pharmacy claims are only available for
prescriptions that were paid through the
patients’ insurance. Administrative datasets
do not capture instances where patients
received drug samples or paid cash for their
prescription. However, this was a cohort
comparison study and there is no reason to
expect that the rate of any of these
occurrences would have differed between the
two study groups. In addition, a days’ supply
within pharmacy claims often does not
provide a true representation of the days
that could potentially be covered given each
patient’s dosage, as demonstrated by the
median days’ supply of 30 days for all six
basal insulin-delivery device combinations in
this study. The adjustment factor used in the
present study was an approximation meant to
account for the general pattern of insulin fills
and provides an estimated days’ supply that
1218 Adv Ther (2015) 32:1206–1221
the authors believe is more accurate than the
days’ supply directly from pharmacy claims.
The study population was comprised of MAPD
members from a large national managed care
organization. However, these patients were
residing primarily in the southern and
Midwestern states of the US. Therefore, the
results of the study may not be generalizable
beyond the studied health plan. Additionally,
because this was an observational,
retrospective claims-based study, its results
are indicative of associations of time with
medication use variables rather than any
causal relationships among those variables.
Nonetheless, the results of this study draw
attention to important relationships that
govern medication adherence and persistence
and may warrant further exploration.
CONCLUSIONS
Elderly patients with T2DM often suffer from
multiple comorbid conditions and may find it
difficult to maintain adherence and persistence
to insulin therapy, which compromise glycemic
control. This study in a mostly elderly MAPD
population found that patients using pens and
those using vials and syringes to administer
basal insulin had some differing characteristics,
but following adjustments for these differences,
a significantly higher rate of adherence and
persistence was noted with use of a pen device
for insulin delivery than when using vials and
syringes. While it seems intuitive that pens
would offer a greater degree of convenience and
simplicity than vials and syringes, additional
research is needed to further examine the
clinical outcomes and economic ramifications
of these administration techniques in an elderly
demographic.
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